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Why & what did we do? 
Why? 
• Gold standard 
• Bladder cancer incidence rates are highest in developed 
countries, especially Northern America and Europe 
• BCG treatment induction & maintenance has significant 
benefits, but also has significant side effects that tend to be 
seen within the first 12 months of treatment 
• To analyse the reasons for treatment interruption in everyday 
clinical practice in a large district hospital 
 
How did we do it? 
• Appropriate ethical approval 
• Quantitative data  
– 01/01/04 – 31/12/11 
– Retrospective case note review of 
234 cases 
– Diagnosis of NMIBC, grade 3 Ta/1 or 
CIS, aged 18 years or over 
– Conaught Strain 
– Administered as per SWOG 
– Collected using a specially designed 
data extraction tool 
– Convenience sample 
– Analysed through IBM SPSS v20 
What did we find? 
• Issues 
– Data extraction tool 
– Paper to electronic 
– Recorded information 
• Results 
– 61% > 70yrs.  From these: 
– 92% completed induction, 80% started maintenance 
– 56% completed 1 year and 5% completed 3 years 
– 43% received counselling 
– 10% nurse specialist contact details 
– 65% had at least 1 symptom (45% within 35 days) 
– 40% experienced pain 
Conclusion & next steps 
• Conclusion 
– Severe toxicity resulted in discontinuation of therapy in the 
majority 
– The majority withdraw in the first year 
– Surprising that those who had contact with a nurse 
specialist or received written information were more likely 
to withdraw 
– Targeted support 
• Next steps 
– Interview patients who have withdrawn for their 
experience 
– Look at the consultation e.g. grade of Dr 
– Review our practice 
